Dasatinib is primarily used to treat chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) that is Philadelphia chromosome-positive (Ph+). It is especially effective in cases where patients are resistant or intolerant to prior therapies, including imatinib.
